Amicus Therapeutics Q1 2026 Earnings Report

Amicus Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.05
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Amicus Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $163.71 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Amicus Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 5/7/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Amicus Therapeutics (NASDAQ:FOLD) (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants. Beyond Fabry disease, Amicus is advancing a pipeline of investigational gene therapies and combination therapies, including programs targeting Pompe disease and Batten disease, with several candidates in late‐stage and mid‐stage clinical development.

Founded in 2005 and headquartered in Cranbury, New Jersey, Amicus Therapeutics completed its initial public offering on the NASDAQ in 2015. The company maintains research and development operations in multiple locations across the United States and Europe, leveraging global manufacturing and regulatory expertise to support its clinical trials and commercial supply chain.

Leadership at Amicus includes Chief Executive Officer Chirfi Guindo, who brings extensive experience in rare disease drug development, and John Crowley, co‐founder and Chairman of the Board. The company collaborates with leading pharmaceutical and academic partners to expand its platform and accelerate the development of novel therapies for underserved patient communities.